About Event

Since Kinase inhibitors have proven to be efficacious and approvable targets, fuelling recent investment into this exciting space as their therapeutic targeting is explored beyond oncology. However, increasing resistance to existing programs and safety bottlenecks threaten further progress. The next wave of kinase targets depends on innovation. 

Join the  2nd Next Generation Kinase Inhibitors Summit  to connect with experts across discovery, R&D, and clinical medicine to discuss how to accelerate the next generation of kinase inhibitor drugs to market, which displays maximal therapeutic efficacy and durable clinical responses. 

IMG_20220329_103243 (1)

Key Unmissable Highlights:


Hear from 20+ KOLs speakers from leading companies such as Genentech, Pfizer, Onconova Therapeutics, MEI Pharma, Volastra Therapeutics, King’s College London School of Medicine, and more


2-days of new jammed-packed content on the progress of relative potential of degradation vs. classical inhibition, RAS/MAPK Signalling pathway, overcoming tumor resistance, and kinase-focussed drug discovery principles


4+ hours of dedicated structured networking time to engage directly with 100+ expert peers from across the field to discuss and share your view on transforming the next generation of Kinase inhibitors  


1 unique scientific poster session to showcase your current work in front of technology and resource providers

What Past Attendees Have Said:

"Focused meeting with some really high-quality science shared and discussed"

Senior Vice President From Black Diamond Therapeutics

"A valuable event because of the quality of the talks and the dialogue following the talks. Very unique opportunity"

President & Chief Executive officer From Onconova Therapeutics

"This meeting was a time well spent, between various great and diverse presentations and networking with colleagues and CROs"

Vice President From TG Therapeutics